Related Experiment Video
Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Resistance mechanisms in anaplastic lymphoma kinase-positive lung cancer
Parnia Behinaein1, Shirish M Gadgeel2, Ramandeep Rattan3
1Department of Surgery, Henry Ford Health, Detroit, MI, United States.
Abstract:
Non-small cell lung cancer has been discovered to have many unique molecular subsets that are associated with different phenotypic behaviors and overall prognoses. In particular, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLCs) have distinctive presentations and disease courses. Patients with ALK NSCLC are typically younger, have significantly less smoking exposure, and often experience prolonged survival. When patients recur, drug-tolerant persister (DTP) cells may be implicated in disease recurrence. In this review we will discuss the phenomenon of DTP related to ALK NSCLC, possible mechanistic explanations and potential treatment strategies to eliminate DTPs.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Inhibition of Cdk Activity

